Phase 3 Study Demonstrates Aranesp® (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome (MDS) Read more about Phase 3 Study Demonstrates Aranesp® (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome (MDS)
Amgen To Present At The Leerink Partners 5th Annual Global Healthcare Conference Read more about Amgen To Present At The Leerink Partners 5th Annual Global Healthcare Conference
Phase 3 Study of BLINCYTO® (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Read more about Phase 3 Study of BLINCYTO® (Blinatumomab) Met Primary Endpoint Of Overall Survival In Patients With B-Cell Precursor Acute Lymphoblastic Leukemia
Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol Read more about Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol
Amgen's 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $10.38 Read more about Amgen's 2015 Revenues Increased 8 Percent To $21.7 Billion And Adjusted Earnings Per Share (EPS) Increased 19 Percent To $10.38
FDA Accepts Amgen's Biosimilar Biologics License Application For ABP 501 Read more about FDA Accepts Amgen's Biosimilar Biologics License Application For ABP 501
Amgen Announces Webcast of 2015 Fourth Quarter and Full Year Financial Results Read more about Amgen Announces Webcast of 2015 Fourth Quarter and Full Year Financial Results
Vectibix® (panitumumab) And Best Supportive Care Improves Overall Survival Compared To Best Supportive Care In Chemorefractory KRAS And RAS Wild-Type Metastatic Colorectal Cancer Read more about Vectibix® (panitumumab) And Best Supportive Care Improves Overall Survival Compared To Best Supportive Care In Chemorefractory KRAS And RAS Wild-Type Metastatic Colorectal Cancer
Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol Read more about Amgen's Repatha® (Evolocumab) Approved As First PCSK9 Inhibitor In Japan For The Treatment Of High Cholesterol
FDA Approves New Kyprolis® (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma Read more about FDA Approves New Kyprolis® (Carfilzomib) Combination Therapy For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
